Drug profile · INN
theophylline sodium glycinate
ASBRON
theophylline sodium glycinate (ASBRON) is a adenosine receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — theophylline sodium glycinate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
theophylline sodium glycinate (ASBRON) is a adenosine receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Adenosine receptor antagonist
Primary target: Adenosine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is theophylline sodium glycinate?
theophylline sodium glycinate (ASBRON) is a adenosine receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for theophylline sodium glycinate?
ASBRON is a marketed brand name for theophylline sodium glycinate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of theophylline sodium glycinate?
theophylline sodium glycinate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.